Anna Ma
Impact in
-
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
-
- Lymphoma Diagnosis and Treatment
Papers in
-
- Histone Deacetylase Inhibitors Research 6
- Protein Degradation and Inhibitors 3
- Ubiquitin and proteasome pathways 1
- Oncology 4
- CAR-T cell therapy research 3
- Cancer Immunotherapy and Biomarkers 1
- Peptidase Inhibition and Analysis 1
- Co-authors
- Manish R. Patel (4 shared papers)Kevin R. Kelly (3 shared papers)Anas Younes (3 shared papers)Ian W. Flinn (3 shared papers)Yasuhiro Oki (4 shared papers)David Tuck (2 shared papers)Amanda Copeland (2 shared papers)Sattva S. Neelapu (2 shared papers)
- Journals
- Blood (3 papers)The Lancet Oncology (1 paper)Journal of Clinical Oncology (1 paper)Clinical Cancer Research (1 paper)Haematologica (1 paper)
- Partner nations
- United StatesSouth KoreaSpain
In The Last Decade
Anna Ma
8 papers receiving 394 citations
Peers
Comparison fields: 5 of 40
- Oncology 161
- Pathology and Forensic Medicine 75
- Genetics 44
- Molecular Biology 251
- Immunology 47
Countries citing papers authored by Anna Ma
This map shows the geographic impact of Anna Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Ma more than expected).
Fields of papers citing papers by Anna Ma
This network shows the impact of papers produced by Anna Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Ma. The network helps show where Anna Ma may publish in the future.
Co-authors
The 25 scholars most cited alongside Anna Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 162 | |
| 2 | 2017 | 106 | |
| 3 | 2014 | 73 | |
| 4 | 2017 | 47 | |
| 5 | 2024 | 5 | |
| 6 | 2015 | 4 | |
| 7 | 2013 | 3 | |
| 8 | 2016 | 1 |
About Anna Ma
Anna Ma is a scholar working on Molecular Biology, Oncology, Pathology and Forensic Medicine, Immunology and Biomedical Engineering, having authored 8 papers that have together received 401 indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (6 papers), Protein Degradation and Inhibitors (3 papers), CAR-T cell therapy research (3 papers), Lymphoma Diagnosis and Treatment (2 papers), Ubiquitin and proteasome pathways (1 paper), Cancer Immunotherapy and Biomarkers (1 paper), Immunotherapy and Immune Responses (1 paper) and Peptidase Inhibition and Analysis (1 paper). The work is most often cited by research in Oncology (161 citations), Pathology and Forensic Medicine (75 citations), Genetics (44 citations), Molecular Biology (251 citations) and Immunology (47 citations). Anna Ma has collaborated with scholars based in United States, South Korea and Spain. Frequent co-authors include Manish R. Patel, Kevin R. Kelly, Anas Younes, Ian W. Flinn, Yasuhiro Oki, David Tuck, Amanda Copeland, Sattva S. Neelapu, John F. Gerecitano and Lucy Gong. Their work appears in journals such as Blood, The Lancet Oncology, Journal of Clinical Oncology, Clinical Cancer Research and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.